Literature DB >> 9884841

Comparison of various in vitro susceptibility methods for testing Stenotrophomonas maltophilia.

K C Carroll1, S Cohen, R Nelson, D M Campbell, J D Claridge, M W Garrison, J Kramp, C Malone, M Hoffmann, D E Anderson.   

Abstract

A total of 57 clinical isolates were screened by disk diffusion for a related pharmacodynamic study. Testing was performed using National Committee for Clinical Laboratory Standards guidelines, except that results were interpreted at 16 to 18 h and 48 h. Of the 57 isolates, 19 were randomly chosen for additional comparative susceptibility testing of five methods (disk diffusion, Etest, Alamar colorimetric broth microdilution, Vitek, and MicroScan) and an in-house broth microdilution method. The two diffusion methods (disk and Etest) had the closest correlation. The commercial broth microdilution methods and the in-house microdilution method generated inconsistent results for all agents except trimethoprim-sulfamethoxazole. Vitek compared poorly with both diffusion and microbroth dilution methods. The most significant discrepancies were evident with all methods when the incubation period was extended to 48 h. When results were interpreted at 48 h, the incidence of resistance for all bactericidal agents was approximately double the resistance observed at 16 to 18 h. The bacteriostatic agents, trimethoprim-sulfamethoxazole and doxycycline, demonstrated the greatest in vitro activity and were least influenced by extended incubation with diffusion methods. Because correlative in vivo and in vitro studies have not revealed an effective therapeutic regimen for serious S. maltophilia infections, susceptibility results with all testing methods should be interpreted with caution when choosing therapy for patients with life-threatening infections. Susceptibility testing for this heterogeneous group remains controversial and routine testing, with the possible exception of doxycycline (or minocycline) and trimethoprim-sulfamethoxazole, should be avoided. Our data support that if testing is done with bactericidal agents, consideration should be given to interpretation after 48-h incubation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9884841     DOI: 10.1016/s0732-8893(98)00089-3

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  8 in total

1.  Antimicrobial susceptibilities of unique Stenotrophomonas maltophilia clinical strains.

Authors:  S Valdezate; A Vindel; E Loza; F Baquero; R Cantón
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

Review 2.  Antimicrobial therapy for Stenotrophomonas maltophilia infections.

Authors:  A C Nicodemo; J I Garcia Paez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-04       Impact factor: 3.267

3.  Evaluation of treatment outcomes for Stenotrophomonas maltophilia bacteraemia.

Authors:  B Lakatos; B Jakopp; A Widmer; R Frei; H Pargger; L Elzi; M Battegay
Journal:  Infection       Date:  2014-03-14       Impact factor: 3.553

4.  The antimicrobial susceptibility of Stenotrophomonas maltophilia isolates using three different methods and their genetic relatedness.

Authors:  Müserref Tatman-Otkun; Saban Gürcan; Burçin Ozer; Bayram Aydoslu; Sebnem Bukavaz
Journal:  BMC Microbiol       Date:  2005-05-09       Impact factor: 3.605

5.  Infection and colonization by Stenotrophomonas maltophilia: antimicrobial susceptibility and clinical background of strains isolated at a tertiary care centre in Hungary.

Authors:  Emese Juhász; Gergely Krizsán; György Lengyel; Gábor Grósz; Júlia Pongrácz; Katalin Kristóf
Journal:  Ann Clin Microbiol Antimicrob       Date:  2014-12-31       Impact factor: 3.944

Review 6.  How to manage lung infiltrates in adults suffering from haematological malignancies outside allogeneic haematopoietic stem cell transplantation.

Authors:  Georg Maschmeyer; J Peter Donnelly
Journal:  Br J Haematol       Date:  2016-01-05       Impact factor: 6.998

7.  Stenotrophomonas maltophilia Susceptibility Testing Challenges and Strategies.

Authors:  Daniel D Rhoads
Journal:  J Clin Microbiol       Date:  2021-08-18       Impact factor: 5.948

8.  Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).

Authors:  G Maschmeyer; J Carratalà; D Buchheidt; A Hamprecht; C P Heussel; C Kahl; J Lorenz; S Neumann; C Rieger; M Ruhnke; H Salwender; M Schmidt-Hieber; E Azoulay
Journal:  Ann Oncol       Date:  2014-05-15       Impact factor: 32.976

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.